Patient and donor characteristics
Patient age, y, mean ± SD | 45 ± 10 |
| No. of male patients (%) | 27 (47) |
| Donor age, y, mean ± SD | 43 ± 10 |
| Female donor, n (%) | 32 (56) |
| Diagnosis, n (%) | |
| Renal cell carcinoma | 25 (43) |
| Breast carcinoma | 12 (21) |
| Melanoma | 5 (9) |
| Ovarian carcinoma | 5 (9) |
| Soft tissue sarcoma | 4 (7) |
| Other diagnosis* | 6 (11) |
| Previous autologous transplantation, n (%) | 13 (23) |
| Disease status prior to transplantation, n (%) | |
| Progressive disease | 39 (68) |
| Stable disease | 18 (32) |
| ATG dose, n (%) | |
| 5-10 mg/kg | 17 (30) |
| 2.5 mg/kg | 40 (70) |
| Total ATG dose, mg/kg, mean ± SD | 267 ± 184 |
| Graft source, n (%) | |
| Bone marrow | 16 (28) |
| PBSC | 41 (72) |
| Day-90 donor chimerism | |
| Studied patients | 40 |
| Full donor chimera, n (%) | 37 (93) |
| Days to full chimera, mean ± SD | 52 ± 26 |
| Donor lymphocyte infusion | |
| Patients, n (%) | 20 (35) |
| Day of first DLI, mean ± SD | 151 ± 131 |
| Acute GVHD | |
| Grades I-IV, n (%) | 37 (65) |
| Grades II-IV, n (%) | 24 (42) |
| Day of onset grades II-IV acute GVHD, mean ± SD | 43 ± 23 |
| Chronic GVHD | |
| Evaluable, n | 42 |
| Limited/extensive, n | 17/8 |
| Day of onset, mean ± SD | 120 ± 30 |
Patient age, y, mean ± SD | 45 ± 10 |
| No. of male patients (%) | 27 (47) |
| Donor age, y, mean ± SD | 43 ± 10 |
| Female donor, n (%) | 32 (56) |
| Diagnosis, n (%) | |
| Renal cell carcinoma | 25 (43) |
| Breast carcinoma | 12 (21) |
| Melanoma | 5 (9) |
| Ovarian carcinoma | 5 (9) |
| Soft tissue sarcoma | 4 (7) |
| Other diagnosis* | 6 (11) |
| Previous autologous transplantation, n (%) | 13 (23) |
| Disease status prior to transplantation, n (%) | |
| Progressive disease | 39 (68) |
| Stable disease | 18 (32) |
| ATG dose, n (%) | |
| 5-10 mg/kg | 17 (30) |
| 2.5 mg/kg | 40 (70) |
| Total ATG dose, mg/kg, mean ± SD | 267 ± 184 |
| Graft source, n (%) | |
| Bone marrow | 16 (28) |
| PBSC | 41 (72) |
| Day-90 donor chimerism | |
| Studied patients | 40 |
| Full donor chimera, n (%) | 37 (93) |
| Days to full chimera, mean ± SD | 52 ± 26 |
| Donor lymphocyte infusion | |
| Patients, n (%) | 20 (35) |
| Day of first DLI, mean ± SD | 151 ± 131 |
| Acute GVHD | |
| Grades I-IV, n (%) | 37 (65) |
| Grades II-IV, n (%) | 24 (42) |
| Day of onset grades II-IV acute GVHD, mean ± SD | 43 ± 23 |
| Chronic GVHD | |
| Evaluable, n | 42 |
| Limited/extensive, n | 17/8 |
| Day of onset, mean ± SD | 120 ± 30 |
ATG indicates antithymocyte globulin; and GVHD, graft-versus-host disease.
Other diagnoses include colorectal carcinoma (n = 1), gastric carcinoma (n = 1), nephroblastoma (n = 1), primitive neuro-ectodermal tumor (n = 1), prostate carcinoma (n = 1), and uterus carcinoma (n = 1).